Illumina, Inc. (ILMN)

NMS – Real Time Price. Currency in USD

145.70

+3.19 (2.24%)

At close: May 12, 2026, 4:00 PM EDT

146.77

+1.07 (0.73%)

Pre-market: May 13, 2026, 4:01 AM EDT

06.05.2026

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

05.05.2026

Here's Why Illumina (ILMN) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

01.05.2026

ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up

Illumina stock jumps after Q1 earnings and revenue beat, with margin expansion and raised 2026 outlook signaling continued growth momentum.

01.05.2026

Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript

01.05.2026

Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

29.04.2026

Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.

27.04.2026

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videos

10.11.2025

Neutral

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

20.10.2025

Neutral

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

Press releases

16.04.2026

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalization, and machine learning features boost analytical capabilities across applications SAN DIEGO, April 16, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software (v4.5), one of the most substantial expansions of the software's capabilities to date. As genomic researchers contend with complex regions of the genome, degraded samples, and multiomic data types, DRAGEN v4.5 delivers new ways to reduce noise, improve accuracy, and extract biological signals, giving researchers greater discovery power to fuel findings in rare disease and oncology.

14.04.2026

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease.

02.04.2026

Illumina Announces Changes to Board of Directors

David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S.

18.03.2026

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Illumina, Inc. (ILMN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Illumina, Inc. (ILMN)

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Here's Why Illumina (ILMN) is a Strong Growth Stock

ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up

Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript

Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Videos

Press releases

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Illumina Announces Changes to Board of Directors

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Here's Why Illumina (ILMN) is a Strong Growth Stock

ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up

Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript

Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Videos

Press releases

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Illumina Announces Changes to Board of Directors

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Search stocks

Illumina, Inc. (ILMN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Illumina, Inc. (ILMN)

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Here's Why Illumina (ILMN) is a Strong Growth Stock

ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up

Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript

Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Videos

Press releases

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Illumina Announces Changes to Board of Directors

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Here's Why Illumina (ILMN) is a Strong Growth Stock

ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up

Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript

Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Videos

Press releases

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Illumina Announces Changes to Board of Directors

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing